Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

850 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men.
Fujimoto S, Hatano K, Banno E, Motooka D, De Velasco MA, Kura Y, Toyoda S, Hashimoto M, Adomi S, Minami T, Yoshimura K, Oka T, Hata J, Matsushita M, Takao T, Takada S, Tsujimura A, Kojima Y, Obara W, Nakamura S, Uemura H, Nonomura N, Fujita K. Fujimoto S, et al. Among authors: hatano k. Cancer Sci. 2024 Dec 3. doi: 10.1111/cas.16408. Online ahead of print. Cancer Sci. 2024. PMID: 39628067 Free article.
One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients.
Kawashima A, Takayama H, Arai Y, Tanigawa G, Nin M, Kajikawa J, Imazu T, Kinoshita T, Yasunaga Y, Inoue H, Nishimura K, Takada S, Nishimura K, Tsujimura A, Nonomura N; Osaka Renal Cell Carcinoma Clinical Study Collaboration. Kawashima A, et al. Eur J Cancer. 2011 Jul;47(10):1521-6. doi: 10.1016/j.ejca.2011.04.001. Epub 2011 May 6. Eur J Cancer. 2011. PMID: 21550799
Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
Tanigawa G, Kawashima A, Yamaguchi S, Nishimura K, Miyoshi S, Kajikawa J, Meguro N, Yosioka T, Oka T, Hara T, Takayama H, Nonomura N; Osaka Renal Cell Carcinoma Clinical Study Collaboration. Tanigawa G, et al. Jpn J Clin Oncol. 2011 Nov;41(11):1265-70. doi: 10.1093/jjco/hyr137. Epub 2011 Sep 29. Jpn J Clin Oncol. 2011. PMID: 21965163
A retroperitoneal primary undifferentiated pleomorphic sarcoma.
Nakamura M, Yamanaka K, Kato T, Hatano K, Kakuta Y, Kawashima A, Fukuhara S, Nonomura N. Nakamura M, et al. Among authors: hatano k. Urol Case Rep. 2024 Jan 20;53:102664. doi: 10.1016/j.eucr.2024.102664. eCollection 2024 Mar. Urol Case Rep. 2024. PMID: 38283659 Free PMC article.
Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
Nagahara A, Uemura M, Sato M, Nakata W, Tsujihata M, Takao T, Matsumura S, Nishimura K, Takada S, Iwanishi T, Kobayashi Y, Ishizuya Y, Takada T, Okada K, Inoue H, Kato T, Hatano K, Kawashima A, Ujike T, Fujita K, Nonomura N. Nagahara A, et al. Among authors: hatano k. Jpn J Clin Oncol. 2024 May 7;54(5):584-591. doi: 10.1093/jjco/hyae004. Jpn J Clin Oncol. 2024. PMID: 38305451 Free PMC article.
Fatal tumoral hemorrhage from brain metastases of renal cell carcinoma after stereotactic radiotherapy and immune checkpoint inhibitor and vascular endothelial growth factor-targeted therapy combinations.
Iwasa K, Nakazawa S, Kato T, Hatano K, Kawashima A, Fukuhara S, Nonomura N. Iwasa K, et al. Among authors: hatano k. IJU Case Rep. 2024 Mar 4;7(3):225-229. doi: 10.1002/iju5.12708. eCollection 2024 May. IJU Case Rep. 2024. PMID: 38686061 Free PMC article.
850 results